Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
This study, called RAISE-XT, is for existing participants in a trial looking at a medicine called zilucoplan. It focuses on people living with a muscle weakness condition known as generalized myasthenia gravis (gMG). The main goal is to understand how well zilucoplan works and how safe it is over a longer period. By continuing to follow people who have already taken the medicine, researchers can gather important information about its long-term effects. This helps us learn more about zilucoplan as a treatment option for gMG, hoping to improve care for those with the condition. It’s an extension of previous studies, meaning it continues to observe people who have already started the treatment.
Överblick
Vad handlar denna studie om?
This study, known as RAISE-XT, is designed for people who have generalized myasthenia gravis (gMG) and have already taken part in a previous study testing a medicine called zilucoplan. Generalized myasthenia gravis is a condition that causes muscle weakness in different parts of the body, which can make everyday tasks difficult. Zilucoplan is a new treatment being investigated for this condition. The earlier studies looked at how zilucoplan worked over a shorter period.
This new study is an 'open-label extension', which means that participants and the study team will know that everyone involved is receiving zilucoplan. It's about seeing how the medicine works and if it's safe when used for a longer time. By continuing to gather information from people who have already tried zilucoplan, researchers hope to get a clearer picture of its long-term benefits and any side effects.
The main aim is to understand if zilucoplan can help manage gMG symptoms effectively over many months or even years, and if it continues to be a safe treatment option. This kind of long-term study is very important because it helps doctors and patients make informed decisions about treatments for chronic conditions like gMG, ultimately aiming to improve quality of life.
Viktiga punkter
- This study is for long-term follow-up of zilucoplan.
- It's for people with generalized myasthenia gravis.
- You must have been in a previous zilucoplan study.
- The goal is to check long-term safety and how well it works.
- You'll be closely monitored by doctors.
- Du kan sluta delta när som helst.
Vem kan vara berättigad?
This study is specifically for adults who have already taken part in a study for zilucoplan, a medicine being tested for generalized myasthenia gravis. If you've been in one of those previous zilucoplan studies, you might be able to join this one.
You cannot join this study if you are currently taking part in another clinical trial where you are receiving an experimental treatment. This is to make sure that any effects seen are clearly due to zilucoplan and not another new medicine. However, you can still be in studies that are just observing health or collecting information, as long as they don't involve new medicines.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- I have generalized myasthenia gravis.
- I have already participated in an earlier study for zilucoplan.
- Jag är 18 år gammal eller äldre.
- I am not currently taking part in another study testing a new experimental medicine.
Vad innebär deltagande?
If you decide to join this study, you will continue to receive the medicine zilucoplan. The study team will regularly check your health, how your generalized myasthenia gravis symptoms are doing, and if you have any side effects. This will involve regular visits to the study clinic, where you might have physical exams, blood tests, and answer questions about your well-being. The exact number and frequency of visits, as well as the total length of your participation, will be clearly explained by the study team. They will continue to monitor your progress over an extended period to understand the long-term effects of zilucoplan.
Potentiella risker och fördelar
Platser (70)
- Mg0011 41Verifierat postnummerMobile, USA
- Mg0011 116Verifierat postnummerPhoenix, USA
- Mg0011 31Verifierat postnummerIrvine, USA
- MG0011 4Verifierat postnummerLos Angeles, USA
- Mg0011 220Verifierat postnummerPasadena, USA
- Mg0011 160Verifierat postnummerSan Francisco, USA
- Mg0011 24Verifierat postnummerNew Haven, USA
- Mg0011 27Verifierat postnummerWashington D.C., USA
- Mg0011 25Verifierat postnummerTampa, USA
- Mg0011 135Verifierat postnummerAugusta, USA
- Mg0011 188Verifierat postnummerGlenview, USA
- Mg0011 156Verifierat postnummerIndianapolis, USA
Vanliga frågor
What is 'open-label'?
Open-label means that everyone involved, including you and the study doctors, knows that you are receiving the study medicine, zilucoplan.
Who is zilucoplan for?
Zilucoplan is a medicine being studied for people who have generalized myasthenia gravis, a condition causing muscle weakness.
Can I join if I'm on another new medicine?
No, you cannot join if you are currently taking part in another study that tests an experimental treatment.
Vad innebär en 'Fas 3'-studie?
Phase 3 is usually one of the final steps in testing a new medicine, looking at its effectiveness and safety in a larger group of people before it might become widely available.
What happens after the study ends?
The study team will explain what medical care options are available to you once your participation in the study is complete.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.